Latest Breaking News On - Julie masow - Page 2 : comparemela.com

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Pharma AG: Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland
China
Toronto
Ontario
Canada
Sunnybrook
Alberta
Ivrea
Piemonte
Italy
United-states
Haiyan

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2.

United-states
Haiyan
Yunnan
China
Italy
Sasayama
Hyogo
Japan
Canada
Spain
Zhejiang
Zaragoza

Novartis Scemblix® shows superior major molecular response

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for.

Philadelphia
Pennsylvania
United-states
Switzerland
America
Michael-meo
Zain-iqbal
Richard-jarvis
Satoshi-sugimoto
Parag-mahanti
Jonathan-graham
Imke-kappes

Novartis Pharma AG: Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Novartis Pharma AG: Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
Hochhaus
Bayern
Germany
Switzerland
Philadelphia
Pennsylvania
America
Sloan-simpson
Parag-mahanti
Jonathan-graham
Isabella-zinck

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

FDA approval of the company’s second US Radioligand Therapy manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the.

United-states
Zaragoza
Baja-california
Mexico
China
Japan
Spain
Ivrea
Piemonte
Italy
Sasayama
Hyogo